FDA
-
-
-
-
-
-
-
PolyPid completes FDA submission for surgical infection prevention drug
-
-
-
-
-
-
-
PolyPid receives $4.3 million FDA fee waiver for drug application
-
-
-
-
-
-
-
PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on PolyPid Ltd. (PYPD)
-
-
-
-
-
-
-
PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results
-
-
-
-
-
-
-
PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal
-
327,801 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

